DBV Technologies to Attend Upcoming Investor Conferences
(Thomson Reuters ONE) -
Press Release
Montrouge, France, May 20, 2016
DBV Technologies to Attend Upcoming Investor Conferences
DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market:
DBVT), a clinical-stage specialty biopharmaceutical company, today announced
that members of its management team will present and host investor meetings at
the following investor events:
* Susanna Mesa, Senior Vice President, Strategy, will present at the UBS
Global Healthcare Conference in New York, NY, on Monday, May 23, 2016 at
3:30 pm ET
* Susanna Mesa, Senior Vice President, Strategy, will present at the Barclays
West Coast Biopharma Conference in Calistoga, CA, on Wednesday, June
1, 2016 at 1:30 pm PT.
* Charles Ruban, Chief Commercial Officer, and Susanna Mesa, Senior Vice
President, Strategy, will present at the Jefferies 2016 Healthcare
Conference in New York, NY, on Tuesday, June 7, 2016, at 3:30 pm ET.
A live webcast of the Jefferies 2016 Healthcare Conference will be available on
the Investor Relations section of the Company's website: http://www.dbv-
technologies.com/en/investor-relations. A replay of the presentation will also
be available on DBV's website within 48 hours after the event.
About DBV Technologies
DBV Technologies developed Viaskin®, a proprietary technology platform with
broad potential applications in immunotherapy. Viaskin is based on epicutaneous
immunotherapy, or EPIT®, DBV's method of delivering biologically active
compounds to the immune system through intact skin. With this new class of self-
administered and non-invasive product candidates, the company is dedicated to
safely transforming the care of food allergic patients, for whom there are no
approved treatments. DBV's food allergies programs include ongoing clinical
trials of Viaskin Peanut and Viaskin Milk, and preclinical development of
Viaskin Egg. DBV is also pursuing a human proof concept clinical study of
Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring
potential applications of its platform in vaccines and other immune diseases.
DBV Technologies has global headquarters in Montrouge, France and New York, NY.
Company shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN
code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global
Select Market in the form of American Depositary Shares (each representing one-
half of one ordinary share) (Ticker: DBVT). For more information on DBV
Technologies, please visit our website: www.dbv-technologies.com
DBV Technologies Contact
Susanna Mesa
Senior Vice President, Strategy
+1 212-271-0861
susanna.mesa(at)dbv-technologies.com
Media Contacts
Erinn White, Centron PR
+1 646-722-8822
ewhite(at)centronpr.com
Marion Janic, Rooney & Associates
+1 212-223-4017
mjanic(at)rooneyco.com
Media Contacts, Europe
Caroline Carmagnol, Alize RP - Relation Presse
+33 (0)6 64 18 99 59
caroline(at)alizerp.com
PDF Version:
http://hugin.info/156437/R/2013661/746310.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: DBV Technologies via GlobeNewswire
[HUG#2013661]
Unternehmensinformation / Kurzprofil:
Datum: 20.05.2016 - 07:30 Uhr
Sprache: Deutsch
News-ID 472533
Anzahl Zeichen: 4156
contact information:
Town:
Bagneux
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 338 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DBV Technologies to Attend Upcoming Investor Conferences"
steht unter der journalistisch-redaktionellen Verantwortung von
DBV Technologies (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
